Engineered T cells are the T cells made
out of the research carried out in the areas of molecular biology and
tissue engineering. These are specifically modified T cells widely used
in the treatment of several autoimmune disorders occurring in the
therapeuti c areas of skin diseases, orthopedic problems, cardiovascular
and neurodegenerative diseases, immune deficient disorders, and cancer.
Delivery of engineered T cells in the body stimulates the immune system
and changes antigen escape. Engineered T cells are inserted in the body
to target cancer cells for effective treatment and to overcome
immunosuppressive tumor environments.
Rise in prevalence of cancer, high demand
for innovative biopharmaceutical therapies, Aging population, rapid
growth in emerging economies, and technical advancements in developed
countries are the major factors fueling the growth of the Engineered T
Cells Market. Additionally, targeted drug delivery and fewer side
effects are the advantages provided by therapies using engineered T
cells.
The global engineered T cells market can
be segmented based on type, application, end-user, and region. In terms
of type, the global market can be categorized into tumor infiltrating
lymphocytes, chimeric antigen receptor (CAR), and T cell receptor (TCR)
The chimeric antigen receptor segment dominates the global market and is
projected to lead the market in the near future owing to increase in
the use of chimeric antigen receptor (CAR) in research and development.
However, the T cell receptor segment is expected to expand at the
fastest CAGR in the near future. Based on application, the global
engineered T cells market can be classified into lung cancer, breast
cancer, colorectal cancer, melanoma, leukemia, and others. The lung
cancer segment accounted for the largest market share and the trend is
expected to continue in the near future due to rise in number of lung
cancer cases and increase in the use of engineered T cells in the
treatment of lung cancer. Based on end-user, the global market can be
divided into hospitals, cancer research centers, and clinics. The
hospitals segment dominated the market and is expected to continue its
dominance during the forecast period.
Based on region, the global engineered T
cells market can be segmented into North America, Latin America, Europe,
Asia Pacific, and Middle East & Africa. North America dominated the
global market owing to a large number of leading companies and
expansion of research and development activities in the U.S. Increased
medical reimbursement and advanced health care are also driving the
market in the region. High demand for lung cancer treatment is drives
the market in North America. Furthermore, the market in Asia Pacific is
projected to grow at a rapid pace because of the large consumer pool,
and rise in income and health care expenditure. China and India account
for significant shares of the market in Asia Pacific. However, high cost
of biotechnologically derived medicines and stringent regulatory
policies are likely to restrain the market in the region.
The global engineered T cells market is
dominated by key players such as Autolus Limited, Cells Medica, Gilead
Sciences, Inc., Novartis AG, Pfizer, Inc., Precision Bioscience,
Bellicum Pharmaceuticals, Eli Lilly and Company, Redmile Group LLC, Unum
Therapeutics, Inc., Juno Therapeutics, Inc., and Oxford Biomedica.
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment